Cargando…
OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer
Approximately 75% of breast cancers are classified as hormone receptor-positive, most of which are estrogen receptor alpha-positive (ER+), which is the primary driver of growth in these tumors. Consequently, endocrine or anti-estrogen therapy is used for treatment. However, despite the benefits of e...
Autores principales: | Bahnassy, Shaymaa, Benitez, Carlos, Cruz, M Idalia, Guerra, Yanira, Ma, Shihong, Persaud, Sonali, Raj, Ganesh, Riggins, Rebecca, Stires, Hillary, Olukoya, Ayodeji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629283/ http://dx.doi.org/10.1210/jendso/bvac150.1822 |
Ejemplares similares
-
SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020) -
Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2023) -
Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023) -
THU495 Glutamate Metabolic Enzymes GLUD1/2 And GPX4 Are Associated with Tumor Size In Black Women With Invasive Lobular Breast Cancer
por: Young, Todd, et al.
Publicado: (2023) -
OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ERα Breast Cancer
por: Perone, Ylenia, et al.
Publicado: (2019)